OMS 824

Drug Profile

OMS 824

Alternative Names: OMS-643762; OMS-824

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nura
  • Developer Omeros Corporation
  • Class Antipsychotics
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Suspended Schizophrenia

Most Recent Events

  • 16 Mar 2017 Omeros Corporation has patent protection for OMS 824 in USA and ex-US countries
  • 15 Mar 2016 Omeros plans to submit a phase II clinical trial protocol to the US FDA, for the treatment of Schizophrenia (Omeros, Form 10-K, March 2016)
  • 08 Mar 2016 Phase-II development for Huntington's disease and Schizophrenia is ongoing in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top